| 37.06 1.94 (5.52%) | 12-08 12:10 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.38 |
1-year : | 51.84 |
| Resists | First : | 38 |
Second : | 44.38 |
| Pivot price | 33.48 |
|||
| Supports | First : | 32.67 |
Second : | 29.38 |
| MAs | MA(5) : | 34.95 |
MA(20) : | 32.73 |
| MA(100) : | 25.35 |
MA(250) : | 0 | |
| MACD | MACD : | 1.9 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 93.8  |
D(3) : | 93.5 |
| RSI | RSI(14): 84.2 |
|||
| 52-week | High : | 38 | Low : | 7.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ INDV ] has closed above the upper band by 15.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 19.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.31 - 35.43 | 35.43 - 35.54 |
| Low: | 34.01 - 34.16 | 34.16 - 34.31 |
| Close: | 34.87 - 35.09 | 35.09 - 35.29 |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Mon, 08 Dec 2025
Indivior stock hits all-time high at 37.72 USD By Investing.com - Investing.com South Africa
Sun, 07 Dec 2025
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge - sharewise.com
Sun, 07 Dec 2025
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge - Yahoo Finance
Thu, 20 Nov 2025
Indivior Concludes Legacy U.S. Department of Justice Matter - PR Newswire
Mon, 17 Nov 2025
Indivior (INDV) Price Target Increased by 151.69% to 37.45 - Nasdaq
Thu, 30 Oct 2025
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 125 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 79.9 (%) |
| Shares Short | 5,050 (K) |
| Shares Short P.Month | 6,010 (K) |
| EPS | 0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.66 |
| Profit Margin | 10.5 % |
| Operating Margin | 36.9 % |
| Return on Assets (ttm) | 13 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 7.91 |
| Sales Per Share | 9.43 |
| EBITDA (p.s.) | 2.59 |
| Qtrly Earnings Growth | 106.3 % |
| Operating Cash Flow | 177 (M) |
| Levered Free Cash Flow | 141 (M) |
| PE Ratio | 37.77 |
| PEG Ratio | 0 |
| Price to Book value | -22.3 |
| Price to Sales | 3.92 |
| Price to Cash Flow | 26.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|